Exicure, Inc. (NASDAQ:XCUR) Sees Large Decline in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the target of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 22,700 shares, a decrease of 16.2% from the January 31st total of 27,100 shares. Based on an average daily volume of 600,700 shares, the short-interest ratio is currently 0.0 days. Currently, 6.0% of the company’s shares are short sold.

Hedge Funds Weigh In On Exicure

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC purchased a new stake in Exicure, Inc. (NASDAQ:XCUR) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned about 0.48% of Exicure as of its most recent SEC filing. Institutional investors own 42.82% of the company’s stock.

Exicure Stock Down 30.3 %

Shares of Exicure stock opened at $9.95 on Thursday. Exicure has a 52 week low of $1.44 and a 52 week high of $36.00. The business’s fifty day simple moving average is $10.81 and its 200-day simple moving average is $8.63. The firm has a market cap of $25.93 million, a PE ratio of -4.81 and a beta of 3.76.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.